Dec 13, 2023 / 01:00PM GMT
Operator
Good day, and welcome to the Vertex Pharmaceuticals review of VX-548 Phase 2 Results in Diabetic Peripheral Neuropathy Conference Call. (Operator Instructions) I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead.
Susie Lisa - Vertex Pharmaceuticals Incorporated - SVP of IR
Thanks, Chuck. Good morning, everyone. I'm Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to this conference call to discuss results from Vertex's Phase 2 study of VX-548 in diabetic peripheral neuropathy, or DPN. Making prepared remarks on today's call, we have Dr. Reshma Kewalramani, Vertex's CEO and President.
Joining her for the question-and-answer portion of the call are Stuart Arbuckle, Chief Operating Officer; and Charlie Wagner, Chief Financial Officer. We recommend that you access the webcast live as you listen to this call. The call is being recorded, and a replay will be available on our website.
We will make forward-looking statements on this call that are subject to the risks and
Vertex Pharmaceuticals Inc to Host Conference Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot